# Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

> **NCT03360630** · PHASE1,PHASE2 · COMPLETED · sponsor: **Capital Medical University** · enrollment: 60 (actual)

## Conditions studied

- Lung Cancer
- Neoplasms

## Interventions

- **BIOLOGICAL:** Anti-PD-1 plus DC-CIK
- **BIOLOGICAL:** Anti-PD-1 alone

## Key facts

- **NCT ID:** NCT03360630
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03360630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03360630, "Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03360630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*